EirGenix, Inc. 6589
TWSE · Taiwan · Health Technology
TWD 50.80-1.60 (-3.05%)
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
As the global biopharmaceutical industry undergoes rapid restructuring, two powerful forces—policy evolution and supply chain transformation—are reshaping Japan's landscape. On one side, the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have built a solid regulatory framework to accelerate biosimilar development. On the other hand, geopolitical risks and economic policy shifts are driving a stronger focus on domestic production capacity a
PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.